All News
Here's my 'pub test' for whether the warning is appropriate. And, debate aside, I do believe that it behoves any regulator to consider the unintended consequences of their regulation, because regulation has real consequences. 5/ #EULAR2024 https://t.co/aurbAwgl9P
David Liew drdavidliew ( View Tweet)
The original direct comparison study! https://t.co/hqrPKfNW1y
Bella Mehta bella_mehta ( View Tweet)
Computer vision/ image analysis is performing very well in rheumatology and can extend help to low resource settings easily! #EULAR2024 https://t.co/8doM7foriM
Bella Mehta bella_mehta ( View Tweet)
SLE RPI may be used more frequently
and can connect the digital dots! @RheumNow https://t.co/UdVIyZJhJV
Bella Mehta bella_mehta ( View Tweet)
Deep learning models are detecting CPPD in radiographs pretty well!! Abst#0112 #EULAR2024 presented by @ThomasHugle ...@RheumNow https://t.co/9z3VVbyyh0
Links:
Bella Mehta bella_mehta ( View Tweet)
Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0077 Please find an interview with my dear colleague @edvital on the importance of achieving and sustaining B cell depletion for improved clinical response in #lupus #SLE @RheumNow
https://t.co/4rTtFWxSvs https://t.co/4esoFTsgzC
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0124 EULAR recommended target oral Pred =<5mg/d. Should the threshold of LLDAS be changed to LLDAS5? Multicentre study showed the protection gained from mortality, irreversible organ damage accrual and flare was no different btw the two targets @RheumNow #EULARBEST https://t.co/GbP25tTmX8
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0145 Can we reclassify people with ANA+ RMD to improve clinical outcomes & stratify for basket trials? Deep machine learning identified distinct classes of ANA-RMD with distinct phenotypes & predicted long-term outcomes better than the legacy diagnoses @RheumNow https://t.co/W2hmmj0v8Y
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0149 When the Doctor says YES but the patients say NO. Data from UK BILAG-BR in moderate to severe #lupus showed ~half patients who met clinical response did not improve their psychological wellbeing. Factors of discordant: ancestry, damage, SLEDAI-2K @RheumNow https://t.co/9cqcPripA2
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare @RheumNow https://t.co/8IIgPuZUrF
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0187 Can we identify a subgroup of #lupus patients at the outset who may benefit from early intensive therapies inc biologics? Data from an inception cohort showed low complement & cSLEDAI=>9 were assoc w increased risk of intensive therapy need/Tx failure @RheumNow https://t.co/jmahjcqom3
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New targets and new treatments in #Sjogren’s disease:
Long term outcomes of repeat cycles of RTX
#EULAR2024
CB https://t.co/6fL3e33i8N
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Links:
Bella Mehta bella_mehta ( View Tweet)
A fantastic tool LupusGPT by @LupusEurope for our patients to help self-manage #SLE was launched yesterday. Building on information from Lupus100 & supplemented by scientific data and relevant guidelines. I have tried it and worked well. Please disseminate https://t.co/a1qXGZyRE6 https://t.co/LTQM6A8Zq3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated.
Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA
IH https://t.co/RvcONHCLvz
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Today, on National Career Nursing Assistants Day, we celebrate the nursing assistants who enhance the lives of our families and loved ones every day! Take a moment to express your gratitude for their care and hard work. #CareerNurseAssistantsDay https://t.co/Mijr820gnE
Rheumatology Nurses RNSociety ( View Tweet)
40% women above 60yo have #osteoarthritis. 25% have hand OA #EULAR24 https://t.co/9ZaQYIYIxn
Vasco C Romao romaovc ( View Tweet)
predict secukinumab response but left out half of patient population ? selection bias @rheumnow #EULAR2024 https://t.co/K4J6eQV0zh
Peter Nash drpnash ( View Tweet)